Since it has been demonstrated that CLL cells show resistance to venetoclax given high levels of Mcl-1, we combined the Bcl-2 inhibition with an Mcl-1 antagonist. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.